Why Shares of AVEO Hit the Brakes Today

Tivozanib, a cancer drug developed by AVEO Pharmaceuticals and Astellas Pharma, is currently under FDA review. Shares of AVEO fell by 5% today after reporting its Q4 results and offering additional details from tivozanib's phase 3 clinical trial. This news has largely been expected by investors since last summer, and health care analyst Max Macaluso breaks down what happened today in this video.

Is this a cancer-focused biotech to watch?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today -- along with a free year of updates -- simply click here now.

The article Why Shares of AVEO Hit the Brakes Today originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.